Lungcancer
Conditions
Brief summary
1. To build an imaging biobank of 200 patients with lungcancer, including pathologic and molecular characteristics of the tumor (mutational status, circulating DeoxyriboNucleic Acid (DNA) from serum biobank…), staging of the cancer (according to the new 2016 Tumor Node Metastasis (TNM) status, the table that classify non-small cell lungcancer) and follow-up informations (Response to first-line treatment (Response Evaluation Criteria in Solid Tumors (RECIST)), disease-free survival, 1-3 years survival). 2. To propose a simple severity scoring system based on tumor features such as size, doubling time (if available), location, amount of enhancement and necrosis. Such approach has been proposed for glioma evaluation (Visually Accessible Rembrandt Images (VASARI)) but is not available for the lung. The objective is to do better than the Tumor Node Metastasis (TNM) staging. 3. To develop and evaluate an IntraVoxel Incoherent Motion (IVIM) protocol for lungcancer evaluation.
Interventions
OTHERMagnetic Resonance Imaging (MRI)
* Chest MRI during the MRI cerebral * 2 tubes of blood taken during the medical visit
Sponsors
General Electric
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults over 18 years * High suspicion of lungcancer confirmed * Tumor \> 2 cm * Incomplete cerebral staging or not yet realized in the initial consultation of screening
Exclusion criteria
* Lungcancer medical history * During Pregnancy * Contraindications to MRI * Patient not able to understand the information of the protocol, taking into account the state of the brain * Patient unable to keep lying in MRI the necessary time
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event-free survival of patients with lungcancer | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients by histologic subtypes | 3 months, 1 year, 2 years and 3 years |
| Number of patients by mutational profile | 3 months, 1 year, 2 years and 3 years |
| Number of patients with metastases | 3 months, 1 year, 2 years and 3 years |
| Overall survival | 3 months, 1 year, 2 years and 3 years |
| Number of metastases by patient | 3 months, 1 year, 2 years and 3 years |
| Therapeutic responses assessed by scanner/MRI and/or Positron Emission Tomography (PET) based on consensus criteria (RECIST 1.1 and PET Response Criteria in Solid Tumors (PERCIST)) | 3 months, 1 year, 2 years and 3 years |
| Number of patients with brain metastases | 3 months, 1 year, 2 years and 3 years |
Countries
France
Contacts
Primary ContactSabine Helfen
Outcome results
None listed